Conavi Medical Corp.
CNVI.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -91.80% | -92.98% | 309.93% | 144.62% | 175.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -91.80% | -92.98% | 309.93% | 144.62% | 175.32% |
| Cost of Revenue | -98.55% | -101.62% | -31.01% | -17.37% | 20.99% |
| Gross Profit | -89.56% | -89.17% | 13,628.72% | 403.34% | 377.19% |
| SG&A Expenses | 2.74% | -8.18% | -15.43% | -11.75% | 14.22% |
| Depreciation & Amortization | -11.49% | -15.98% | -19.90% | -21.91% | -26.37% |
| Other Operating Expenses | 2.75% | 13.09% | -15.61% | -23.57% | -23.57% |
| Total Operating Expenses | -32.16% | -33.56% | -17.88% | -16.64% | 9.72% |
| Operating Income | 4.23% | 5.45% | 44.93% | 39.57% | 14.39% |
| Income Before Tax | 54.80% | 63.23% | 54.06% | 15.36% | -39.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.80% | 63.23% | 54.06% | 15.36% | -39.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.80% | 63.23% | 54.06% | 15.36% | -39.12% |
| EBIT | 4.23% | 5.45% | 44.93% | 39.57% | 14.39% |
| EBITDA | 4.05% | 5.16% | 45.55% | 39.78% | 13.62% |
| EPS Basic | 95.56% | 96.04% | 95.07% | 53.23% | 2.69% |
| Normalized Basic EPS | 93.32% | 94.62% | 95.86% | 70.85% | 35.45% |
| EPS Diluted | 95.56% | 96.04% | 95.07% | 53.23% | 2.69% |
| Normalized Diluted EPS | 93.32% | 94.62% | 95.86% | 70.85% | 35.45% |
| Average Basic Shares Outstanding | 233.42% | 355.23% | 913.42% | 600.89% | 326.09% |
| Average Diluted Shares Outstanding | 233.42% | 355.23% | 913.42% | 600.89% | 326.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |